Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7698896 | 0.81 | MAPT (0.58) | MAPTTSHRABCC4ALDH1A1LMNA | |
| SCHEMBL176299 | 0.79 | TSHR (0.50) | MAPTTSHRALDH1A1FAAH | |
| SCHEMBL11323317 | 0.79 | TSHR (0.35) | MAPTTSHRABCC4SMN1; SMN2ALDH1A1 | |
| SCHEMBL5167018 | 0.79 | MAPT (0.61) | MAPTTSHRABCC4SMN1; SMN2ALDH1A1 | |
| SCHEMBL9791270 | 0.79 | MAPT (0.61) | MAPTTSHRABCC4SMN1; SMN2ALDH1A1 | |
| SCHEMBL3079525 | 0.79 | GPR84 (0.46) | MAPTTSHRABCC4SMN1; SMN2ALDH1A1 | |
| SCHEMBL11462977 | 0.79 | MAPT (0.61) | MAPTTSHRABCC4SMN1; SMN2ALDH1A1 | |
| SCHEMBL3627376 | 0.79 | ALDH1A1 (0.35) | MAPTTSHRABCC4SMN1; SMN2ALDH1A1 | |
| SCHEMBL11796286 | 0.77 | KMT2A (0.54) | MAPTTSHRALDH1A1FAAH | |
| SCHEMBL9295757 | 0.77 | KMT2A (0.54) | MAPTTSHRALDH1A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | claimed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | claimed |
| EP-1740171-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-01-10 | — | — | EP | claimed |
| WO-2005094816-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | claimed |
| EP-0891371-B1 | 9-OXIMESILYL ERYTHROMYCIN A DERIVATIVES | ABBOTT LAB (US) | 2003-12-10 | — | — | EP | claimed |
| JP-4217962-A | — | — | None | — | — | JP | disclosed |
| EP-4373493-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | Nurix Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4370123-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | Nurix Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024086296-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | MEKANISTIC THERAPEUTICS LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2007016589-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1740171-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006127588-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2005094816-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | disclosed |
| CN-1549817-A | Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them | ��˹��ŵ�� | 2004-11-24 | — | — | CN | disclosed |
| JP-H04217962-A | HYDANTOIN DERIVATIVE | HOECHST AG | 1992-08-07 | — | — | JP | disclosed |
| US-4863947-A | PESTICIDES, INSECTICIDES | ROHM AND HAAS (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MAPT 4484/4885TSHR 2748/4885ABCC4 4/4885 |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | IDO1, IDO2, AANAT | MAPT 292/4885TSHR 3401/4885ABCC4 3456/4885 |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | MAPT 2223/4885TSHR 4040/4885ABCC4 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.